No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Bliss GVS Pharma Limited, founded in 1984 and based in Mumbai, India, operates as a pharmaceutical enterprise focused on the development, production, and commercialization of a vast array of medicinal formulations and general healthcare items. Its comprehensive pharmaceutical offerings span numerous dosage forms, such as capsules, tablets, injections, oral suspensions, topical creams/gels/ointments, effervescent tablets, eye/ear drops, transdermal patches, and parenterals. In addition to prescription pharmaceuticals, the company manufactures a wide selection of over-the-counter (OTC) and personal care products, including balms, lotions, shampoos, soaps, nasal inhalers, and various sprays and solutions. Addressing a broad spectrum of medical conditions, Bliss GVS's therapeutic catalogue features anti-infectives (e.g., antibacterial, anti-malarial, anti-fungal), anti-inflammatory agents, analgesics, gastrointestinal treatments (such as anti-ulcer and anti-diarrheal medications), anti-diabetics, respiratory support products (like antitussives and nasal decongestants), and an extensive range of nutritional, dermatological, and general wellness supplements, including vitamins, body supplements, and specialized hygiene solutions. The company's products are also distributed internationally through its export operations.
www.blissgvs.comNo one on the platform currently holds BLISSGVS.BO.
No tracked institution reports a position in BLISSGVS.BO as of their last filing.
No one on the platform has traded BLISSGVS.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 7.8% | 8.9% | 10.7% | — | — | — |
| Rev. Growth % | 14.5% | 10.3% | ||||
| Profit Margin % | 13.9% | 9.1% | 11.3% | |||
| Free Cash Flow Margin % | 8.8% | 5.8% | 5.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $3.8B | +6.1% | $6.99 | $6.99–$6.99 | — | 1 |
| 2028 | $9.6B | +155.8% | $9.92 | $9.92–$9.92 | — | 1 |
| 2029 | $8.7B | -9.8% | $13.12 | $13.12–$13.12 | — | 1 |
| 2030 | $10.1B | +16.2% | $14.00 | $14.00–$14.00 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 1 of the last 2 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2025-07-22 | $3.90 | $4.08 | +4.6% |
| 2025-01-28 | $2.89 | $2.27 | -21.5% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| BLISSGVS.BOBliss GVS Pharma Limited | $679.90 | -0.94% | $72.5B | — |
| BAJAJHCARE.BOBajaj Healthcare Ltd | $320.95 | +0.19% | $10.7B | — |
| BAJAJHCARE.NSBajaj Healthcare Ltd | $321.10 | +0.06% | $10.8B | — |
| HESTERBIO.BOHester Biosciences Limited | $2184.70 | +0.78% | $18.6B | — |
| HESTERBIO.NSHester Biosciences Limited |
| $2207.70 |
| +1.65% |
| $18.8B |
| — |
| JAGSNPHARM.BOJagsonpal Pharmaceuticals Limited | $228.10 | +1.11% | $15.0B | — |
| JAGSNPHARM.NSJagsonpal Pharmaceuticals Limited | $228.28 | +1.08% | $15.0B | — |
Source: Financial Modeling Prep · peers by sector/industry